RecruitingPhase 1NCT04147078

Personalized DC Vaccine for Postoperative Cancer

Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial


Sponsor

Sichuan University

Enrollment

80 participants

Start Date

Jun 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a personalized cancer vaccine made from a patient's own immune cells (called dendritic cells) after surgery. The idea is to "train" the immune system to recognize and attack any remaining cancer cells after a tumor is removed. It's being tested in patients with gastric (stomach), liver, lung, or colorectal cancer who have already had surgery. **You may be eligible if...** - You have been newly diagnosed with stomach cancer, liver cancer, non-small cell lung cancer, or colorectal cancer - You have had surgery or ablation to remove the tumor (with the goal of a cure) - You are in good general health (ECOG 0 or 1) - Your organs (kidneys, liver, blood) are functioning adequately **You may NOT be eligible if...** - There is any evidence your cancer has spread - You have an active infection such as hepatitis B, hepatitis C, HIV, or tuberculosis - You have a blood clotting disorder or immune system condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALDC vaccine subcutaneous administration

subcutaneous administration


Locations(1)

Qiu Li

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04147078


Related Trials